Comparative Effectiveness of the Dexamethasone Intravitreal Implant in Vitrectomized and Non-vitrectomized Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion
Authors:
- Michael R. PetersenMPMichael R. Petersen
- Robert A. SiskRSRobert A. Sisk
- Robert E. FosterRFRobert E. Foster
- Christopher D. RiemannCRChristopher D. Riemann
- Daniel M. MillerDMDaniel M. Miller
- 1 January 2013
- journal article
- research article
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 44 (1) , 28-33
Abstract
BACKGROUND AND OBJECTIVE: To compare duration and efficacy of the dexamethasone (DEX) intravitreal implant in vitrectomized (pars plana vitrectomy [PPV] group) and non-vitrectomized eyes (control group) with macular edema related to central retinal vein occlusion (CRVO). PATIENTS AND METHODS: Eyes that received the DEX implant for CRVO related to macular edema were included in a retrospective chart review. Outcomes measured were best-corrected visual acuity (BCVA) and central macular thickness (CMT). RESULTS: Fifteen eyes were included in the study. Eight of 15 eyes had prior vitrectomy. Mean BCVA was 20/160 in both groups. Baseline mean CMT was 550 μm (PPV group) and 556 μm (control group, P = .70), and improved to 307.5 μm (PPV group) and 316.3 μm (control group) ( P = .90) after implant. The BCVA was 20/125 (PPV group) and 20/200 (control group) ( P = .60). Time to next procedure was similar in both groups. CONCLUSIONS: This retrospective study shows similar CMT reductions with DEX implant treatment for CRVO-related macular edema in vitrectomized and non-vitrectomized eyes.Keywords
This publication has 16 references indexed in Scilit:
- Natural History of Visual Outcome in Central Retinal Vein OcclusionOphthalmology, 2011
- Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein OcclusionOphthalmology, 2010
- A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein OcclusionArchives of Ophthalmology (1950), 2009
- DIFFERENCE IN CLEARANCE OF INTRAVITREAL TRIAMCINOLONE ACETONIDE BETWEEN VITRECTOMIZED AND NONVITRECTOMIZED EYESRetina, 2005
- Optical Coherence Tomography Findings After an Intravitreal Injection of Bevacizumab (Avastin®) for Macular Edema From Central Retinal Vein OcclusionOphthalmic Surgery, Lasers and Imaging Retina, 2005
- Letter to the EditorRetina, 1996
- Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatmentGraefe's Archive for Clinical and Experimental Ophthalmology, 1987
- Experimental and Clinical Observations of the Intraocular Toxicity of Commercial Corticosteroid PreparationsAmerican Journal of Ophthalmology, 1986
- Treatment of Intraocular Proliferation with Intravitreal Injection of Triamcinolone AcetonideAmerican Journal of Ophthalmology, 1980
- Retinal branch vein occlusionSurvey of Ophthalmology, 1978